<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>A Predictive Model for Synergistic Oncolytic Virotherapy: Unveiling the Ping-Pong Mechanism and Optimal Timing of Combined Vesicular Stomatitis and Vaccinia Viruses - Health AI Hub</title>
    <meta name="description" content="We present a mathematical model that describes the synergistic mechanism of combined Vesicular Stomatitis Virus (VSV) and Vaccinia Virus (VV). The model capture">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>A Predictive Model for Synergistic Oncolytic Virotherapy: Unveiling the Ping-Pong Mechanism and Optimal Timing of Combined Vesicular Stomatitis and Vaccinia Viruses</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2601.10405v1" target="_blank">2601.10405v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2026-01-15
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Joseph Malinzi, Amina Eladdadi, Rachid Ouifki, Raluca Eftimie, Anotida Madzvamuse, Helen M. Byrne
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.QM, math.DS
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2601.10405v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2601.10405v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">We present a mathematical model that describes the synergistic mechanism of combined Vesicular Stomatitis Virus (VSV) and Vaccinia Virus (VV). The model captures the dynamic interplay between tumor cells, viral replication, and the interferon-mediated immune response, revealing a `ping-pong' synergy...</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Medical/health related research</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>Not explicitly an AI application. The paper employs mathematical modeling and numerical simulations to predict outcomes and optimize strategies. While this falls under computational biology and predictive analytics, it does not specify the use of machine learning, deep learning, or other typical AI algorithms for medical applications. These models could potentially inform or be integrated into AI-driven drug discovery or personalized treatment platforms, but the methodology described is not 'medical AI' itself.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>See abstract for details</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>See paper for methodology</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>See abstract</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>Potential clinical applications</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not analyzed</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not analyzed</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">q-bio.QM</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">q-bio.QM</span>
                    
                    <span class="tag tag-keyword">math.DS</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">We present a mathematical model that describes the synergistic mechanism of combined Vesicular Stomatitis Virus (VSV) and Vaccinia Virus (VV). The model captures the dynamic interplay between tumor cells, viral replication, and the interferon-mediated immune response, revealing a `ping-pong' synergy where VV-infected cells produce B18R protein that neutralizes interferon-$Œ±$, thereby enhancing VSV replication within the tumor. Numerical simulations demonstrate that this combination achieves complete tumor clearance in approximately 50 days, representing an 11\% acceleration compared to VV monotherapy (56 days), while VSV alone fails to eradicate tumors. Through bifurcation analysis, we identify critical thresholds for viral burst size and B18R inhibition, while sensitivity analysis highlights infection rates and burst sizes as the most influential parameters for treatment efficacy. Temporal optimization reveals that therapeutic outcomes are maximized through immediate VSV administration followed by delayed VV injection within a 1-19 day window, offering a strategic approach to overcome the timing and dosing challenges inherent in OVT.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>